Atria-selective antiarrhythmic drugs in need of alliance partners.
Antiarrhythmic drugs
Atria-selective ion channels
Atrial fibrillation
Upstream therapy
Journal
Pharmacological research
ISSN: 1096-1186
Titre abrégé: Pharmacol Res
Pays: Netherlands
ID NLM: 8907422
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
05
02
2019
revised:
30
04
2019
accepted:
03
05
2019
pubmed:
7
5
2019
medline:
28
5
2020
entrez:
7
5
2019
Statut:
ppublish
Résumé
Atria-selective antiarrhythmic drugs in need of alliance partners. Guideline-based treatment of atrial fibrillation (AF) comprises prevention of thromboembolism and stroke, as well as antiarrhythmic therapy by drugs, electrical rhythm conversion, ablation and surgical procedures. Conventional antiarrhythmic drugs are burdened with unwanted side effects including a propensity of triggering life-threatening ventricular fibrillation. In order to solve this therapeutic dilemma, 'atria-selective' antiarrhythmic drugs have been developed for the treatment of supraventricular arrhythmias. These drugs are designed to aim at atrial targets, taking advantage of differences in atrial and ventricular ion channel expression and function. However it is not clear, whether such drugs are sufficiently antiarrhythmic or whether they are in need of an alliance partner for clinical efficacy. Atria-selective Na
Identifiants
pubmed: 31059791
pii: S1043-6618(19)30219-1
doi: 10.1016/j.phrs.2019.104262
pii:
doi:
Substances chimiques
Anti-Arrhythmia Agents
0
Ion Channels
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
104262Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.